Scarica l'app Stockscreener
820.40
0.73%
-6.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$826.57
Aprire:
$825.07
Volume 24 ore:
666.32K
Relative Volume:
0.15
Capitalizzazione di mercato:
$776.13B
Reddito:
$53.26B
Utile/perdita netta:
$13.80B
Rapporto P/E:
54.40
EPS:
15.0808
Flusso di cassa netto:
$-50.20M
1 W Prestazione:
-4.07%
1M Prestazione:
+7.30%
6M Prestazione:
+11.66%
1 anno Prestazione:
-10.46%
Intervallo 1D:
$819.26
$834.70
Intervallo di 1 settimana:
$806.00
$864.35
Portata 52W:
$623.78
$935.62
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
820.04 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.54 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
226.73 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.65 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.12 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly teams up with Indiana Latino Expo to enhance healthcare access - WISH-TV
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Eli Lilly taps Goldman Sachs Asset Management for $25 billion OCIO deal - Pensions & Investments
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead - MarketBeat
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes - investor.lilly.com
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs - Benzinga
Eli Lilly Stock Price ForecastLLY Soars to $860 After Orforglipron Breakthrough - TradingNEWS
Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition (NYSE:LLY) - Seeking Alpha
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial - BioSpace
Lilly's weight-loss pill shows better blood sugar control in late-stage trials - Reuters
Eli Lilly's orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins - Fierce Biotech
Eli Lilly (LLY) Advances Diabetes Treatment with Orforglipron Su - GuruFocus
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Diab - GuruFocus
Eli Lilly oral obesity drug succeeds in diabetes trial (LLY) - Seeking Alpha
Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data - Yahoo Finance
Driven by the Engine of Innovation, Eli Lilly Leads a New Era in Healthcare - NAI500
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly - Stocktwits
Major Shareholder Sells Millions in Eli Lilly Stock! - TipRanks
1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today - The Globe and Mail
Lilly Endowment sells $3.16 million in Eli Lilly shares - Investing.com
Eli Lilly eyes 2027 approval for new obesity drug: CEO - Nikkei Asia
Independence Bank of Kentucky Buys Another $3.1 Million Eli Lilly (NYSE: LLY) Shares - The Globe and Mail
Eli Lilly (LLY) Upgraded to 'Buy' Amid Promising Growth Catalysts - GuruFocus
Eli Lilly doubles down on Mounjaro despite rising competition in Brazil - Valor International
The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa - Nasdaq
Erste Group upgrades Eli Lilly stock rating to Buy after strong H1 results - Investing.com Canada
Top Stock Reports for Apple, Eli Lilly & Visa - Nasdaq
Eli Lilly and Company Strengthens Presence Among S&P 500 Companies - Kalkine Media
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Lilly Wants To Know: What Does Chronic Illness Really Look Like? 10/13/2025 - MediaPost
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years - Yahoo Finance
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Oct 2025) - 24/7 Wall St.
Eli Lilly Opens R&D Incubator for Life Sciences Startups - San Diego Business Journal
Aspen wins approval to market Lilly's Mounjaro for weight loss in South Africa - Reuters
Should Omvoh’s Clinical Success and Earnings Optimism Prompt Action from Eli Lilly (LLY) Investors? - simplywall.st
Should Omvoh’s Clinical Results and Innovation Drive a Rethink of Eli Lilly’s (LLY) Specialty Focus? - Yahoo Finance
The Goldman Sachs Group Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Insider Sales Surge: Block, Eli Lilly, Strategy, P&G, Dell - TipRanks
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Should Investors Buy Eli Lilly Stock? - The Globe and Mail
Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and more - Endpoints News
Gunderson Capital Management Inc. Increases Position in Eli Lilly and Company $LLY - MarketBeat
Seeking Safe Havens: Why Pfizer and Eli Lilly Are Top Market Picks Now? - NAI500
Eli Lilly (LLY): Revisiting Valuation After Recent Share Price Gains - simplywall.st
Lilly Endowment sells Eli Lilly shares worth $9.04 million - Investing.com
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$9.04 Million in Common Stock - 富途牛牛
Lilly Endowment unloads about $600 million in Eli Lilly stock during early October - Sherwood News
Eli Lilly’s New Study on Weight Reduction Drugs: A Potential Market Game-Changer? - TipRanks
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters
Next Medicine Deal After Pfizer? Analysts, Shares Point to AstraZeneca, Eli Lilly - Money US News.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):